Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/17/2025 | $64.00 | Outperform → Market Perform | BMO Capital Markets |
| 3/13/2025 | Hold → Buy | Kepler | |
| 3/3/2025 | Buy → Hold | Stifel | |
| 2/12/2025 | Equal-Weight | Morgan Stanley | |
| 1/6/2025 | Underperform → Mkt Perform | Bernstein | |
| 5/30/2024 | $156.00 | Buy | Goldman |
| 4/12/2024 | $163.00 | Outperform | BMO Capital Markets |
| 1/23/2024 | $120.00 | Overweight | Morgan Stanley |
Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy® through NovoCare® PharmacyRo and LifeMD collaborations continue based on their commitment to providing safe and effective medical treatment for patients living with chronic diseases; dialogue with other companies ongoingA new $299 savings offer, available from July 1 – July 31, 2025, is designed to help new self-paying patients previously prescribed unapproved "semaglutide" start on FDA-approved Wegovy®PLAINSBORO, N.J., June 26, 2025 /PRNewswire/ -- Novo Nordisk continues expansion of patient access to Wegovy® (semaglutide) injection 2.4 mg through a new collaboration
Collaboration of over one month has ended based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at riskNovo Nordisk won't stop taking action to protect Americans from the dangers of illicit foreign active pharmaceutical ingredients in knock-off drugsEfforts will continue to make authentic, FDA-approved Wegovy® directly available through NovoCare® Pharmacy to select telehealth organizations that share our commitment to safe and effective medical treatment for patients living with chronic diseases PLAINSBORO, N.J., June 23, 2025 /PRNewswire/ -- Novo Nordisk announced today that the company will no longer be working with Hims
With all doses of FDA-approved Wegovy® fully available nationwide, it is illegal under US compounding laws to make or sell knockoff "semaglutide" drugs, with rare exceptionsNew, one-time $199 first-month offer for Wegovy® available through June 30, 2025; offer designed to help new self-paying patients previously prescribed unapproved "semaglutide" start on FDA-approved Wegovy® "Choose the Real Thing" campaign launching to raise awareness about the dangers of knockoff "semaglutide"Novo Nordisk intensifies legal actions aimed at protecting patients from risks and dangers associated with compounded "semaglutide" drugs and their foreign illicit active ingredientsPLAINSBORO, N.J., May 22, 2025 /P
BMO Capital Markets downgraded Novo Nordisk A/S from Outperform to Market Perform and set a new price target of $64.00
Kepler upgraded Novo Nordisk A/S from Hold to Buy
Stifel downgraded Novo Nordisk A/S from Buy to Hold
For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Cardiovascular disease is a gr
11-K - NOVO NORDISK A S (0000353278) (Filer)
11-K - NOVO NORDISK A S (0000353278) (Filer)
6-K - NOVO NORDISK A S (0000353278) (Filer)
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a
NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) -- ExlService Holdings, Inc. (NASDAQ:EXLS), a leading global data analytics and digital operations and solutions company, today announced that Andreas Fibig, a seasoned global executive with a strong record of innovation across industries and geographies, has been appointed to EXL's Board of Directors as an independent director effective Jan. 10, 2023. Fibig will be a member of the Board's Audit and Nominating and Governance Committees. "Andreas is a distinguished global business leader with more than 25 years of international health care, pharmaceutical, and consumer industry experience," said Vikram S. Pandit, Chairman of the Board of EXL. "We lo
LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 30,575 shares of common stock and 8,750 restricted stock units (“RSUs”) to be distributed among six new employees with a grant date of Dec. 1, 2020 (the “Inducement Grants”). The stock options approved under the Inducement Grants were issued pursuant to Dicerna’s 2016 Inducement Plan and have an exercise price per share equal to $24.76,